cp wire

CP Wire Articles


Arrayit Corporation (OTC: ARYC) announced on 7/02/2018 that the company has completed an allergy testing pilot program for one of nation’s largest chains of retail stores.  The retailer... read more

Mon, 07/2/18 - 09:46 am
CP Staff



Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a... read more

Mon, 07/2/18 - 09:26 am
CP Staff
  • Application based on data from PH III KEYNOTE-407 trial
  • PDUFA target date set for 10/30/2018


Merck (NYSE:MRK) announced on 7/02/2018 that the U.S. Food and Drug... read more

Mon, 07/2/18 - 09:16 am
CP Staff

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced on 6/29/2018 detailed data from the ADVANCE Phase 3 study which showed that Rolontis had an absolute risk reduction of severe neutropenia... read more

Fri, 06/29/18 - 09:58 am
CP Staff



Kite, a Gilead Company (Nasdaq: GILD) announced on 6/29/2018 that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion... read more

Fri, 06/29/18 - 09:42 am
CP Staff

Argenx (Euronext & Nasdaq: ARGX) announced on 6/28/2018 the achievement of the second of two preclinical milestones towards... read more

Thu, 06/28/18 - 09:57 am
CP Staff

Arsanis, Inc. (NASDAQ:ASNS) announced on 6/28/2018 the discontinuation of its Phase 2 clinical trial of ASN100 for the prevention of S. aureuspneumonia in high-risk, mechanically ventilated... read more

Thu, 06/28/18 - 09:43 am
CP Staff
  • Combined company will be named Akebia Therapeutics, Inc.
  • Company will focus on patients with chronic kidney disease
  • Combined portfolio can address the needs of an estimated... read more
Thu, 06/28/18 - 09:17 am
CP Staff

Cedilla Therapeutics  announced on 6/28/2018 the appointment of three vice presidents with extensive experience in drug discovery to advance the company’s mission of harnessing existing protein... read more

Thu, 06/28/18 - 09:05 am
CP Staff

Some important/interesting microbiome related news for the week ending 6-24-18:

Axial Biotherapeutics and the... read more

Wed, 06/27/18 - 07:51 pm
CP Staff

Med Device Sales and Marketing professionals and C-Suite familiar with the terms Value-Based, Generic and Commoditized products.

Value-based Products are "good enough" and... read more

Wed, 06/27/18 - 06:59 pm
Dave Martinez_Nashville

Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) announcedon 6/27/2018 that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the... read more

Wed, 06/27/18 - 10:07 am
CP Staff
  • Glasdegib combined with chemotherapy almost doubled overall survival compared to chemotherapy alone
  • PDUFA goal date is set in December of 2018
  • Ph III trials began enrolling... read more
Wed, 06/27/18 - 09:49 am
CP Staff

Purdue Pharma announced on 6/27/2018 successful completion of a first-in-human Phase 1 dose escalation study of tinostamustine in patients with relapsed or refractory hematological malignancies... read more

Wed, 06/27/18 - 09:33 am
CP Staff

After six companies raised approximately $720 million last week four more IPOs are planned this week seeking to raise $500 million plus.

... read more

Tue, 06/26/18 - 05:29 pm
CP Staff

Kaleido Biosciences, announced on 6/25/2018 that it has closed $101 million in an oversubscribed Series C financing. Several new investors participated in the financing, including a wholly-owned... read more

Tue, 06/26/18 - 02:01 pm
CP Staff

Arcus Biosciences, Inc. (NYSE:RCUS) and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced on 6/26/2018 that they have entered into a clinical collaboration to evaluate two triple combination... read more

Tue, 06/26/18 - 09:23 am
CP Staff

The FDA approved on 6/21/2018 the Eversense Continuous Glucose Monitoring (CGM) system for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to... read more

Fri, 06/22/18 - 10:27 am
CP Staff
  • Primary endpoint was the pathological Complete Response Rate
  • The main secondary endpoint was the resection margin status evaluating the quality of surgery
  • NBTXR3 accumulates... read more
Fri, 06/22/18 - 10:09 am
CP Staff

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.